Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (181-190 of 791) with videos related to

Pageof 80
Sort By:
Journal of Cancer Research and Clinical Oncology|March 10, 2017
Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemiaVerena S Hoffmann, Joerg Hasford, Michael Deininger, et al.
Blood|October 23, 2012
Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitorsElias Jabbour, Van Morris, Hagop Kantarjian, et al.
Cancers|August 29, 2024
Global Trial Representation and Availability of Tyrosine Kinase Inhibitors for Treatment of Chronic Myeloid LeukemiaMycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, et al.
Cancer|February 28, 2007
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patternsHagop M Kantarjian, Jorge Cortes, Francçois Guilhot, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2013
Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remissionAlfonso Quintás-Cardama, Srdana Grgurevic, Uri Rozovski, et al.
Leukemia Research|July 16, 2003
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemiaEfrosyni Apostolidou, Jorge Cortes, Apostolia Tsimberidou, et al.
Blood|June 26, 2023
Representation of the population in need for pivotal clinical trials in lymphomasMycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, et al.
Cancer|March 15, 2006
t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapyC Cameron Yin, Jorge Cortes, Bedia Barkoh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 8, 2009
A multinational study of health state preference values associated with chronic myelogenous leukemiaShelagh M Szabo, Adrian R Levy, Catherine Davis, et al.
Clinical Lymphoma & Myeloma|March 27, 2007
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challengesElias Jabbour, Jorge Cortes, Susan O'Brien, et al.
Pageof 80

Showing results (181-190 of 791) with videos related to

Sort By:
Pageof 80
Journal of Cancer Research and Clinical Oncology|March 10, 2017
Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemiaVerena S Hoffmann, Joerg Hasford, Michael Deininger, et al.
Blood|October 23, 2012
Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitorsElias Jabbour, Van Morris, Hagop Kantarjian, et al.
Cancers|August 29, 2024
Global Trial Representation and Availability of Tyrosine Kinase Inhibitors for Treatment of Chronic Myeloid LeukemiaMycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, et al.
Cancer|February 28, 2007
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patternsHagop M Kantarjian, Jorge Cortes, Francçois Guilhot, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2013
Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remissionAlfonso Quintás-Cardama, Srdana Grgurevic, Uri Rozovski, et al.
Leukemia Research|July 16, 2003
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemiaEfrosyni Apostolidou, Jorge Cortes, Apostolia Tsimberidou, et al.
Blood|June 26, 2023
Representation of the population in need for pivotal clinical trials in lymphomasMycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, et al.
Cancer|March 15, 2006
t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapyC Cameron Yin, Jorge Cortes, Bedia Barkoh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 8, 2009
A multinational study of health state preference values associated with chronic myelogenous leukemiaShelagh M Szabo, Adrian R Levy, Catherine Davis, et al.
Clinical Lymphoma & Myeloma|March 27, 2007
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challengesElias Jabbour, Jorge Cortes, Susan O'Brien, et al.
Pageof 80